SCHEMBL23788255

SCHEMBL23788255

C[C@H](N)C(=O)OCOC(=O)Nc1ncccc1-c1cc(Cc2ccc(COc3ccccn3)cc2)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
CYP2C19 P33261 5/20 0.37
CYP1A2 P05177 4/20 0.37
CYP2C9 P11712 3/20 0.37
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.33
CYP2D6 P10635 3/20 0.33
GAA P10253 1/20 0.33
ACACB O00763 1/20 0.32
PPIA P62937 4/20 0.32
NPC1 O15118 5/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RAB9A P51151 2/20 0.31
CYP3A4 P08684 1/20 0.31
SMPD1 P17405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26368792 0.90 MAPT (0.39) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL23788253 0.88 SMN1; SMN2 (0.43) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL23788258 0.87 MAPT (0.34) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL29318143 0.87 SMN1; SMN2 (0.39) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL26367242 0.86 SMN1; SMN2 (0.38) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL23788251 0.84 MAPT (0.39) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL13784389 0.84 HPGD (0.36) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL2944987 0.84 SMN1; SMN2 (0.40) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL29318080 0.83 SMN1; SMN2 (0.36) MAPTHPGDSMN1; SMN2NPY1RNPY2R
SCHEMBL23788247 0.83 HPGD (0.37) MAPTHPGDSMN1; SMN2NPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771688-B2 Pyridine derivatives substituted by heterocyclic ring and amino group AMPLYX PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-11771688-B2 Pyridine derivatives substituted by heterocyclic ring and amino group AMPLYX PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210275510-A1 PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210275510-A1 PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP ERG28, PDXK, PAH MAPT 1381/4885HPGD 164/4885SMN1; SMN2 3484/4885
US-11771688-B2 Pyridine derivatives substituted by heterocyclic ring and amino group ERG28, PDXK, PAH MAPT 1381/4885HPGD 164/4885SMN1; SMN2 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.